Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2025
0mins
Source: Globenewswire
Court Ruling in Favor of Quantum BioPharma: The Ontario Court of Appeal dismissed Dr. Raza Bokhari's reconsideration motion regarding his termination as CEO of FSD Pharma, now Quantum BioPharma, leading to a total award of $180,000 against him for wrongful dismissal claims.
Financial Developments and Future Plans: Quantum BioPharma is pursuing the collection of arbitration awards from Dr. Bokhari through U.S. courts, while continuing its focus on developing innovative treatments for neurodegenerative disorders and maintaining strategic investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
